| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 19/12/2024 | 13:45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:XLO | Xilio Therapeutics Inc |
| 19/12/2024 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI | NASDAQ:XLO | Xilio Therapeutics Inc |
| 16/12/2024 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer | NASDAQ:XLO | Xilio Therapeutics Inc |
| 03/12/2024 | 22:30 | GlobeNewswire Inc. | Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:XLO | Xilio Therapeutics Inc |
| 07/11/2024 | 15:25 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:XLO | Xilio Therapeutics Inc |
| 07/11/2024 | 15:15 | GlobeNewswire Inc. | Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors | NASDAQ:XLO | Xilio Therapeutics Inc |
| 07/11/2024 | 15:05 | GlobeNewswire Inc. | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results | NASDAQ:XLO | Xilio Therapeutics Inc |
| 30/10/2024 | 14:01 | GlobeNewswire Inc. | Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | NASDAQ:XLO | Xilio Therapeutics Inc |
| 04/10/2024 | 15:05 | GlobeNewswire Inc. | Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | NASDAQ:XLO | Xilio Therapeutics Inc |
| 02/10/2024 | 23:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/09/2024 | 03:36 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/09/2024 | 03:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/08/2024 | 22:01 | GlobeNewswire Inc. | Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:XLO | Xilio Therapeutics Inc |
| 08/08/2024 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results | NASDAQ:XLO | Xilio Therapeutics Inc |
| 13/06/2024 | 22:05 | GlobeNewswire Inc. | Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors | NASDAQ:XLO | Xilio Therapeutics Inc |
| 14/05/2024 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results | NASDAQ:XLO | Xilio Therapeutics Inc |
| 07/05/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:XLO | Xilio Therapeutics Inc |
| 01/04/2024 | 22:05 | GlobeNewswire Inc. | Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/03/2024 | 12:05 | GlobeNewswire Inc. | Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/03/2024 | 12:00 | Business Wire | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program | NASDAQ:XLO | Xilio Therapeutics Inc |
| 28/02/2024 | 22:01 | GlobeNewswire Inc. | Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference | NASDAQ:XLO | Xilio Therapeutics Inc |
| 31/01/2024 | 22:01 | GlobeNewswire Inc. | Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference | NASDAQ:XLO | Xilio Therapeutics Inc |
| 08/01/2024 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies | NASDAQ:XLO | Xilio Therapeutics Inc |
| 07/12/2023 | 13:30 | GlobeNewswire Inc. | Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data | NASDAQ:XLO | Xilio Therapeutics Inc |
| 09/11/2023 | 22:10 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] | NASDAQ:XLO | Xilio Therapeutics Inc |
| 09/11/2023 | 22:05 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:XLO | Xilio Therapeutics Inc |
| 09/11/2023 | 22:01 | GlobeNewswire Inc. | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results | NASDAQ:XLO | Xilio Therapeutics Inc |
| 03/11/2023 | 17:00 | GlobeNewswire Inc. | Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors | NASDAQ:XLO | Xilio Therapeutics Inc |
| 31/10/2023 | 14:15 | GlobeNewswire Inc. | Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting | NASDAQ:XLO | Xilio Therapeutics Inc |
| 27/09/2023 | 23:02 | GlobeNewswire Inc. | Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting | NASDAQ:XLO | Xilio Therapeutics Inc |